ArriVent BioPharma, Inc.
arrivent.comWhat Do They Do?
Develops cancer medicines, including firmonertinib and antibody-drug conjugates, for patients with lung and other solid tumors.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$49.9MView ↗
- ▲ +59% (Loss)
- vs −$31.4M in Q2 FY2025
-
Aug 12, 2026
Licenses ARR-002 rights in Greater China to Allist
Allist will develop and commercialize ARR-002 in the territory; ArriVent retains rights elsewhere and a manufacturing right there.
Sources
8-K, filed Aug 12, 2026
On August 11, 2026, ArriVent BioPharma, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Allist License…View ↗
Who Do They Compete With?
Competes with AstraZeneca, Johnson & Johnson, Blossom Hill Therapeutics, Dizal Pharmaceutical, Oric Pharmaceuticals, Black Diamond Therapeutics, Cullinan Therapeutics, Taiho Pharmaceutical, Boehringer Ingelheim, and Bayer
10-K for FY2025, filed Mar 5, 2026Companies that compete with us directly on the level of commercialization or development of product candidates targeting EGFR…View ↗
Loading...
